BI-1607 is an engineered antibody that can be viewed as a platform to enhance efficacy and overcome resistance to existing cancer treatments, such as targeted monoclonal antibodies and immune checkpoint inhibitors.
Phase 2a study with BI-1607 in combination with pembrolizumab and ipilimumab
In July 2024, BioInvent announced a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, to evaluate BI-1607 in combination with ipilimumab, and KEYTRUDA® (pembrolizumab) in a Phase 2 study in patients with metastatic melanoma.
Under the terms of the supply agreement, MSD will provide its anti-PD-1 therapy KEYTRUDA to be used in combination with BI-1607 and the CTLA-4 antibody ipilimumab. The open-label Phase 2 study will incorporate several dosing levels of BI-1607 and lower dosing levels of ipilimumab in patients with unresectable or metastatic melanoma.
BI-1607 is an engineered antibody that can be viewed as a platform to enhance efficacy and overcome resistance to existing cancer treatments, such as targeted monoclonal antibodies and immune checkpoint inhibitors. In December 2023, BioInvent presented first clinical data from the Phase 1 dose escalation study evaluating BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors. The data demonstrated the treatment was well tolerated and no serious adverse events related to BI-1607 were observed. Stable disease was observed in 6/11 evaluable patients. Previously in 2021, BioInvent announced proof-of-concept data showing the ability of BI-1607 to overcome resistance to CTLA-4-based therapy.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merk & Co., Inc., Rahway, NJ, USA.